Summary & Overview
CPT 0198U: Navigator RHD/CE Sequencing Test for Rh Antigen Genotyping
CPT code 0198U identifies a Proprietary Laboratory Analyses (PLA) test — the Navigator RHD/CE Sequencing assay from Grifols Immunohematology Center — used to characterize Rh blood group antigen genotypes. This sequencing-based test has clinical importance for reducing immune-mediated incompatibility in transfusion medicine, organ transplantation, and maternal-fetal care. Nationally, PLA codes like 0198U are tracked for unique-test reporting and can affect lab billing, claim adjudication, and utilization monitoring.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the test's clinical role, payer coverage considerations, and typical service and site of care. The publication outlines expected benchmarks for lab-based genetic assays, highlights policy-relevant elements tied to PLA coding, and summarizes the clinical context in which the test is used (transfusion compatibility, transplant planning, and perinatal/newborn evaluation).
This summary provides a national perspective for clinicians, laboratory administrators, and policy analysts on how CPT code 0198U is classified, where it is performed, and why it is clinically relevant in preventing Rh-related incompatibility events.
Billing Code Overview
CPT code 0198U is a Proprietary Laboratory Analyses (PLA) code for the Navigator RHD/CE Sequencing test from Grifols Immunohematology Center. The test analyzes specific gene sequences to determine Rh blood group antigen status, which can inform clinical decisions to minimize adverse blood–type incompatibility reactions in blood transfusions, organ transplants, pregnancy, and care of newborns.
-
Service type: Genetic sequencing-based immunohematology assay performed by a specialized laboratory.
-
Typical site of service: Clinical laboratory or specialized reference laboratory using a blood specimen.
Clinical & Coding Specifications
Clinical Context
A 28-year-old pregnant woman presents for routine prenatal care after a prior pregnancy complicated by hemolytic disease of the newborn. Her obstetrician orders molecular Rh blood group genotyping to clarify maternal and fetal Rh antigen status when serologic typing is inconclusive or when variant Rh alleles are suspected. A blood specimen is collected in the clinic and sent to Grifols Immunohematology Center for the Navigator RHD/CE Sequencing test billed with 0198U. The laboratory performs targeted sequencing of RHD and RHCE gene regions, interprets variants that affect RhD and RhCE antigen expression, and reports results to the ordering clinician. Results inform transfusion planning, antenatal antibody management, and neonatal risk assessment. Typical site of service is an outpatient clinic or hospital outpatient laboratory; the service type is a proprietary laboratory molecular diagnostic test (Proprietary Laboratory Analyses, PLA).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional (interpretive) component of the test if separated from technical component. |
TC |